Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, via a hybrid model. James Martin, CFO and interim co-CEO, will present on-demand starting September 12 at 7:00 a.m. ET. Attendees can engage in virtual one-on-one meetings throughout the conference. Interested investors and industry professionals can register for attendance.

News Market Reaction – COCP

-4.51%

-4.51% Session move

In the trading session that priced this news, COCP declined 4.51%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24^th Annual Global Investment Conference being held September 12-14, 2022.

An on-demand presentation by James Martin, CFO and interim co-CEO, will be available to conference attendees on the H.C. Wainwright platform beginning Monday, September 12 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace. The Cocrystal presentation will be posted to the Company’s website beginning September 12.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

# # #

FAQ

When will Cocrystal Pharma participate in the investment conference?

Cocrystal Pharma will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

Who is presenting on behalf of Cocrystal Pharma at the conference?

James Martin, CFO and interim co-CEO, will present on-demand at the conference.

What is the date and time for the Cocrystal presentation?

The on-demand presentation will be available starting September 12 at 7:00 a.m. Eastern time.

How can investors register for the H.C. Wainwright conference?

Investors can register for the conference virtually or in-person by following the registration link provided in the press release.

Where can I find the Cocrystal presentation after the conference?

The presentation will be posted on Cocrystal Pharma's website starting September 12.